Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants. (UH2/UH3)

The summary for the Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants. (UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants. (UH2/UH3): This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from Institutions in African countries to develop an H3Africa Biorepository in order to provide an international site for the receipt, storage and distribution of samples from H3Africa research projects as well as other African research studies. The NIH is partnering with the Wellcome Trust to provide support for H3Africa, an initiative to enhance the development of sustainable research capacity in Africa that will use genomics as a part of a cutting-edge approach to promote health and combat disease.
Federal Grant Title: Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants. (UH2/UH3)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-RM-12-008
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.172
CFDA Descriptions: Human Genome Research
Current Application Deadline: Oct 31, 2012
Original Application Deadline: Oct 29, 2012
Posted Date: Aug 22, 2012
Creation Date: Oct 26, 2012
Archive Date: Nov 30, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Public and State controlled institutions of higher education - Private institutions of higher education - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed)
NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Op...
Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult ...
Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44)
Near-Term Technology Development for Genome Sequencing - STTR (R41/R42)
Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health
Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com